Non-invasive biomarkers in exacerbations of obstructive lung disease

Respirology

Volumn 18, Issue 5, 2013, Pages 874-884

  Warwick, Geoffrey ^a   Thomas, Paul S ^b,c   Yates, Deborah H ^a  

^a ST VINCENT S HOSPITAL   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c PRINCE OF WALES HOSPITAL   (Australia)

Author keywords

biomarker; exhaled breath condensate; induced sputum; interferon gamma inducible protein 10; neopterin

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; GAMMA INTERFERON INDUCIBLE PROTEIN 10; HYDROGEN PEROXIDE; INTERLEUKIN 6; INTERLEUKIN 8; LEUKOTRIENE B4; NEOPTERIN; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; AIRWAY OBSTRUCTION; ARTICLE; ASTHMA; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CONTROLLED STUDY; DISEASE EXACERBATION; DISEASE SEVERITY; FEMALE; HUMAN; LIMIT OF DETECTION; MAJOR CLINICAL STUDY; MALE; PH; PRIORITY JOURNAL; RESPIRATORY TRACT INFECTION; SPUTUM ANALYSIS; SPUTUM CULTURE; SUPERNATANT;

ADULT; AGED; ASTHMA; BIOLOGICAL MARKERS; BREATH TESTS; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; CHEMOKINE CXCL10; CYTOKINES; DISEASE PROGRESSION; FEMALE; HUMANS; HYDROGEN-ION CONCENTRATION; MALE; MIDDLE AGED; NEOPTERIN; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RESPIRATORY TRACT INFECTIONS; SPUTUM;

EID: 84879393931     PISSN: 13237799     EISSN: 14401843     Source Type: Journal    
DOI: 10.1111/resp.12089     Document Type: Article

References (40)

1. Bush A, Pavord I,. Following Nero: fiddle while Rome burns, or is there a better way? Thorax 2011; 66: 367.
2. Bai TR, Vonk JM, Postma DS, et al. Severe exacerbations predict excess lung function decline in asthma. Eur. Respir. J. 2007; 30: 452-456.
3. Donaldson GC, Wedzicha JA,. COPD exacerbations. 1: epidemiology. Thorax 2006; 61: 164-168.
4. O'Byrne PM, Pedersen S, Lamm CJ, et al. Severe exacerbations and decline in lung function in asthma. Am. J. Respir. Crit. Care Med. 2009; 179: 19-24.
5. Pauwels R, Calverley P, Buist AS, et al. COPD exacerbations: the importance of a standard definition. Respir. Med. 2004; 98: 99-107.
6. Motta A, Paris D, Melck D, et al. Nuclear magnetic resonance-based metabolomics of exhaled breath condensate: methodological aspects. Eur. Respir. J. 2012; 39: 498-500.
7. Hunt J,. Exhaled breath condensate: an evolving tool for noninvasive evaluation of lung disease. J. Allergy Clin. Immunol. 2002; 110: 28-34.
8. Carraro S, Andreola B, Alinovi R, et al. Exhaled leukotriene B4 in children with community acquired pneumonia. Pediatr. Pulmonol. 2008; 43: 982-986.
9. Majewska E, Kasielski M, Luczynski R, et al. Elevated exhalation of hydrogen peroxide and thiobarbituric acid reactive substances in patients with community acquired pneumonia. Respiratory Medicine. 2004; 98: 669-676.
10. Lacoma A, Prat C, Andreo F, et al. Value of procalcitonin, C-reactive protein, and neopterin in exacerbations of chronic obstructive pulmonary disease. Int. J. Chron Obstruct. Pulmon Dis. 2011; 6: 157-169.
11. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. 2008. [Accessed 9 Jan 2012.] Available from URL: http://www.goldcopd.com
12. Papi A, Bellettato CM, Braccioni F, et al. Infections and airway inflammation in chronic obstructive pulmonary disease severe exacerbations. Am. J. Respir. Crit. Care Med. 2006; 173: 1114-1121.
13. British Thoracic Society, Scottish Intercollegiate Guidelines Network (SIGN). British guideline on the management of asthma. Thorax 2003; 58 (Suppl. I): i1-94.
14. Wark PA, Simpson JL, Hensley MJ, et al. Safety of sputum induction with isotonic saline in adults with acute severe asthma. Clin Exp Allergy. 2001; 31: 1745-1753.
15. BTS guidelines for the management of community acquired pneumonia in adults. Thorax 2001; 56 (Suppl. 4): IV1-64.
16. Jones PW, Quirk FH, Baveystock CM,. The St George's Respiratory Questionnaire. Respir. Med. 1991; 85 (Suppl. B): 25-31; discussion 3-7.
17. Horvath I, Hunt J, Barnes PJ, et al. Exhaled breath condensate: methodological recommendations and unresolved questions. Eur. Respir. J. 2005; 26: 523-548.
18. Paggiaro PL, Chanez P, Holz O, et al. Sputum induction. Eur. Respir. J. Suppl. 2002; 37: 3s-8s.
19. Fahy JV, Liu J, Wong H, et al. Cellular and biochemical analysis of induced sputum from asthmatic and from healthy subjects. Am. Rev. Respir. Dis. 1993; 147: 1126-1131.
20. Kostikas K, Papatheodorou G, Ganas K, et al. pH in expired breath condensate of patients with inflammatory airway diseases. Am. J. Respir. Crit. Care Med. 2002; 165: 1364-1370.
21. Hunt J,. Exhaled breath condensate pH assays. Immunol. Allergy Clin. North Am. 2007; 27: 597-606.
22. Beigel J,. The emerging utility of neopterin? Clin. Immunol. 2005; 116: 1-2.
23. Ip M, Rainer TH, Lee N, et al. Value of serum procalcitonin, neopterin, and C-reactive protein in differentiating bacterial from viral etiologies in patients presenting with lower respiratory tract infections. Diagn. Microbiol. Infect. Dis. 2007; 59: 131-136.
24. Rainer TH, Chan CPY, Leung MF, et al. Diagnostic utility of CRP to neopterin ratio in patients with acute respiratory tract infections. J. Infect. 2009; 58: 123-130.
25. Baydar T, Yuksel O, Sahin TT, et al. Neopterin as a prognostic biomarker in intensive care unit patients. J. Crit. Care 2009; 24: 318-321.
26. Cok G, Parildar Z, Basol G, et al. Pleural fluid neopterin levels in tuberculous pleurisy. Clin. Biochem. 2007; 40: 876-880.
27. Wark PAB, Bucchieri F, Johnston SL, et al. IFN-[gamma]-induced protein 10 is a novel biomarker of rhinovirus-induced asthma exacerbations. J. Allergy Clin. Immunol. 2007; 120: 586-593.
28. Quint JK, Donaldson GC, Goldring JJ, et al. Serum IP-10 as a biomarker of human rhinovirus infection at exacerbation of COPD. Chest 2010 Apr; 137: 812-822.
29. Eickmeier O, Huebner M, Herrmann E, et al. Sputum biomarker profiles in cystic fibrosis (CF) and chronic obstructive pulmonary disease (COPD) and association between pulmonary function. Cytokine 2010; 50: 152-157.
30. Montuschi P,. LC/MS/MS analysis of leukotriene B4 and other eicosanoids in exhaled breath condensate for assessing lung inflammation. J. Chromatogr. B. Analyt. Technol. Biomed. Life Sci. 2009; 877: 1272-1280.
31. Montuschi P, Ragazzoni E, Valente S, et al. Validation of leukotriene B4 measurements in exhaled breath condensate. Inflamm. Res. 2003; 52: 69-73.
32. Douwes J, Gibson P, Pekkanen J, et al. Non-eosinophilic asthma: importance and possible mechanisms. Thorax 2002; 57: 643-648.
33. Saetta M, Di Stefano A, Maestrelli P, et al. Airway eosinophilia in chronic bronchitis during exacerbations. Am. J. Respir. Crit. Care Med. 1994; 150 (6 Pt 1): 1646-1652.
34. Malerba M, Montuschi P,. Non-invasive biomarkers of lung inflammation in smoking subjects. Curr. Med. Chem. 2012; 19: 187-196.
35. Montuschi P, Curro D, Ragazzoni E, et al. Anaphylaxis increases 8-iso-prostaglandin F2alpha release from guinea-pig lung in vitro. Eur. J. Pharmacol. 1999; 365: 59-64.
36. Barreto M, Villa MP, Olita C, et al. 8-Isoprostane in exhaled breath condensate and exercise-induced bronchoconstriction in asthmatic children and adolescents. Chest 2009; 135: 66-73.
37. Lucidi V, Ciabattoni G, Bella S, et al. Exhaled 8-isoprostane and prostaglandin E(2) in patients with stable and unstable cystic fibrosis. Free Radic. Biol. Med. 2008; 45: 913-919.
38. Ko FW, Leung TF, Wong GW, et al. Measurement of tumor necrosis factor-alpha, leukotriene B4, and interleukin 8 in the exhaled breath condensate in patients with acute exacerbations of chronic obstructive pulmonary disease. Int. J. Chron Obstruct. Pulmon Dis. 2009; 4: 79-86.
39. Gessner C, Scheibe R, Wotzel M, et al. Exhaled breath condensate cytokine patterns in chronic obstructive pulmonary disease. Respir. Med. 2005; 99: 1229-1240.
40. Montuschi P, Paris D, Melck D, et al. NMR spectroscopy metabolomic profiling of exhaled breath condensate in patients with stable and unstable cystic fibrosis. Thorax 2012; 67: 222-228.